Development of FAPI PET as a Non-invasive Biomarker of Liver Fibrogenesis

The main objective of this research is to gain fundamental information regarding the biology of liver fibrosis and fibrogenesis in patients with known or suspected chronic liver disease (CLD). Approximately 50 subjects with known or suspected chronic liver disease who are referred for a clinical liver biopsy will be included in this research. We aim to gain a fundamental understanding of the disease physiology and pathology using a novel PET/MRI approach, using fibroblast activation protein inhibitor (FAPI) PET imaging and MR elastography (MRE).